GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Chimerix Inc.
Chimerix is a biopharmaceutical company whose fortunes are closely tied to its smallpox drug. Its stock price reflects government purchases of this drug for strategic stockpiles, which is its primary source of revenue.
Share prices of companies in the market segment - General oncology therapy
Chimerix is a biopharmaceutical company developing antiviral drugs and oncology therapies. We've classified it in the "General Oncology" category. The chart below shows how the market values companies with a diversified pipeline across various medical fields.
Broad Market Index - GURU.Markets
Chimerix is a biopharmaceutical company developing drugs to treat cancer and other serious diseases. Its scientific advancements make it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Chimerix shares compare to the overall market.
Change in the price of a company, segment, and market as a whole per day
CMRX - Daily change in the company's share price Chimerix Inc.
For Chimerix, Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reaction to clinical trial news and is an important metric for assessing risk.
Daily change in the price of a set of shares in a market segment - General oncology therapy
Chimerix is a biopharmaceutical company developing drugs to treat cancer and other serious diseases. The biotech sector is known for its high volatility. The chart below shows average daily fluctuations in the industry, allowing you to assess how CMRX's performance aligns with overall trends.
Daily change in the price of a broad market stock, index - GURU.Markets
Chimerix is a pharmaceutical company specializing in the treatment of viral infections and cancer. Its shares are driven by news about new drug developments. This dynamic, specific to the pharmaceutical industry, creates fluctuations that contribute to overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Chimerix Inc.
For Chimerix, Inc., year-over-year performance is a story of its transformation. Its market cap change over the past 12 months reflects its strategic pivot to oncology drug development following the sale of its antiviral drug. Its valuation reflects investors' faith in the success of its new immuno-oncology developments.
Annual dynamics of market capitalization of the market segment - General oncology therapy
Chimerix, as a biotech company, is focused on drug development. Its performance relative to the sector will reflect the level of investor confidence in its scientific platform and ability to successfully conduct clinical trials, which is key for companies at this stage.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Chimerix, a biotech company with an approved product, demonstrates the progression from development to sales with its dynamics. Its performance, compared to the market, reflects investors' assessment of both current revenue and the potential of its remaining pipeline. It's a story of transformation into a fully-fledged pharmaceutical company.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Chimerix Inc.
Chimerix is a biopharmaceutical company with an approved drug. Its monthly performance reflects both revenue from its commercial product and progress in its oncology programs. Sales news and trial data are the main drivers.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
Chimerix is a biopharmaceutical company focused on developing drugs for the treatment of cancer and medical countermeasures against biological threats. The chart below reflects how investors viewed the company's diversified portfolio, which includes both commercial and government priorities.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Chimerix is a biopharmaceutical company focused on developing new cancer treatments. The company's fate depends solely on the success of its clinical trials and regulatory decisions, not on overall economic trends. The broader market chart serves merely as a contrasting backdrop to see how scientific news has given its stock a life of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Chimerix Inc.
Chimerix is a biopharmaceutical company whose main product is a smallpox preventative. Its weekly stock price is driven by government contracts to purchase this drug for strategic stockpiles and news about clinical trials.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
Chimerix develops antiviral drugs and oncology therapies. Its diversified portfolio may mitigate risks, but success still depends on clinical data. The chart will show whether Chimerix's share price movement is driven by news about a specific drug or reflects broader trends in the biotech sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Chimerix is a biotech company. Its shares move on news about clinical trials and regulatory decisions. This chart clearly demonstrates how much its performance is driven by scientific news rather than by general market trends, which create their own path.
Market capitalization of the company, segment and market as a whole
CMRX - Market capitalization of the company Chimerix Inc.
Chimerix's market capitalization tells the story of the biotech company's transformation. Its chart shows how investors valued the sale of its first approved drug and its focus on oncology. The current valuation is a bet on the success of its new scientific platform and drug candidates in development.
CMRX - Share of the company's market capitalization Chimerix Inc. within the market segment - General oncology therapy
Chimerix is a biotechnology company developing antiviral and oncology drugs. Its market capitalization in the pharmaceutical sector is small and highly volatile. Its market capitalization is directly dependent on clinical trial results and regulatory decisions, reflecting the high risk and potential profitability of its developments.
Market capitalization of the market segment - General oncology therapy
Here's a chart showing the biotech sector's market capitalization. Chimerix is a company that successfully developed and sold its first drug and is now using the proceeds to develop a new generation of oncology drugs. Its market history exemplifies a smart strategy that mitigates risk and allows for the funding of bold scientific ideas.
Market capitalization of all companies included in a broad market index - GURU.Markets
Chimerix is a biopharmaceutical company developing drugs to treat oncology. Its market capitalization reflects the potential of its scientific research. The chart below shows the economic weight of companies at the forefront of the fight against cancer.
Book value capitalization of the company, segment and market as a whole
CMRX - Book value capitalization of the company Chimerix Inc.
Chimerix's foundation is its intellectual property in the antiviral drug TEMBEXA and its oncology research. Its book value represents the capital raised from the sale of TEMBEXA to the US government. The chart tells the story of the biotech company, which is using the proceeds to finance its move into oncology.
CMRX - Share of the company's book capitalization Chimerix Inc. within the market segment - General oncology therapy
Chimerix develops antiviral and oncology drugs. The chart shows its share of actual R&D assets. These are its laboratories, where the drug development platform was created, which is its main scientific base.
Market segment balance sheet capitalization - General oncology therapy
Chimerix is a biopharmaceutical company developing drugs to treat serious diseases. Their value lies in their research and patents. The book value chart reflects the value of their R&D base but cannot convey the potential value of their intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
Chimerix's core assets include laboratories and R&D centers for developing antiviral drugs and oncology therapies. The chart shows how the company's scientific and physical capital has evolved over the course of its strategic transformations.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Chimerix Inc.
Chimerix is a biotech company whose value is derived from its pipeline, not its assets. The chart clearly demonstrates how its market capitalization is essentially a bet on the success of one of its drug candidates. You'll see how it rises on positive news and falls on failure, with little correlation to its balance sheet.
Market to book capitalization ratio in a market segment - General oncology therapy
Chimerix is a biopharmaceutical company developing drugs to treat cancer and viral infections. Its valuation depends on the success of its clinical trials and the commercial potential of its lead drug. The chart shows how its market capitalization, based on this potential, relates to its current assets.
Market to book capitalization ratio for the market as a whole
Chimerix is a biotech company whose valuation depends on the success of its scientific developments. This metric clearly illustrates that investors are buying not current assets, but the hope of a future blockbuster. Market capitalization significantly exceeding book value is the norm for promising biotech companies.
Debts of the company, segment and market as a whole
CMRX - Company debts Chimerix Inc.
Chimerix is a biotech company that successfully developed and commercialized its first drug. This chart shows its financial transformation. Now with significant cash, the company is using it to fund its oncology development pipeline, reducing its need for external financing.
Market segment debts - General oncology therapy
Chimerix is a biotech company developing drugs to treat serious diseases, including oncology. After selling its core product, the company focused on new developments. This chart shows how the company's financial strategy is changing as it transforms its research portfolio.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Chimerix Inc.
Chimerix is a biopharmaceutical company focused on oncology. This chart shows its financial structure. For a company that has sold its core commercial product and is focusing on development, a strong balance sheet is essential. Debt is a significant risk factor during the transition period.
Market segment debt to market segment book capitalization - General oncology therapy
Chimerix is a biopharmaceutical company developing drugs to treat oncology. This chart shows the debt burden in the biotech sector. It is an indicator of the company's ability to finance its expensive clinical research and development efforts to develop new cancer treatments.
Debt to book value of all companies in the market
Chimerix is a biopharmaceutical company developing drugs to treat serious diseases. Following the sale of its core product, the company is refocusing its research. This total market debt chart helps assess the company's financing conditions for its new R&D strategy and its reliance on debt.
P/E of the company, segment and market as a whole
P/E - Chimerix Inc.
Chimerix is a biotech company focused on developing oncology drugs. Its lead product, Tembexa, was approved for the treatment of smallpox and sold to Emergent BioSolutions. This chart reflects investor assessments of its research programs and its ability to monetize its developments.
P/E of the market segment - General oncology therapy
Chimerix is a biopharmaceutical company developing drugs to treat serious diseases. Its lead product, Tembexa, is approved for the treatment of smallpox, making it a key biosecurity asset. This chart shows the average valuation for the oncology sector, reflecting how investors value companies with approved drugs for critical needs.
P/E of the market as a whole
Chimerix is a biopharmaceutical company focused on developing oncology treatments. Its valuation depends entirely on the success of its drugs in clinical trials and regulatory approval. Overall market sentiment, as reflected in this chart, is completely irrelevant.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Chimerix Inc.
Chimerix is a biopharmaceutical company focused on developing drugs for the treatment of oncology. This chart reflects analyst expectations for the success of its clinical development. Future profits are entirely dependent on trial results and potential regulatory approval of its drugs.
%20P%2FE%20Chimerix%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Chimerix-Inc.&v=1772513513673 "Chart of the company's future (projected) P/E Chimerix Inc.")
Future (projected) P/E of the market segment - General oncology therapy
Chimerix is a biopharmaceutical company developing drugs for the treatment of serious diseases, including oncology. Their lead drug is designed to reduce the toxicity of chemotherapy. The chart reflects average profitability expectations for the biotech sector. CMRX's position relative to this benchmark reflects the market's assessment of the commercial potential of their lead product and pipeline.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772513513737 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
Chimerix, Inc. is a biopharmaceutical company developing oral antiviral drugs for immunocompromised patients. Its key product is designed to prevent smallpox. This chart of general market expectations provides a backdrop for evaluating companies working in the biodefense and pandemic preparedness sectors, where demand can be unpredictable.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513513803 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Chimerix Inc.
Chimerix is a biotech company developing drugs to treat serious diseases, including cancer. Its financial performance, as shown in the graph, depends on sales of its approved drug TEMBEXA (for the treatment of smallpox) and on the progress of clinical trials in its oncology programs.
Profit of companies in the market segment - General oncology therapy
Chimerix is a biopharmaceutical company developing drugs to treat cancer and other serious diseases. Its lead candidate, ONC201, has shown promise in the treatment of gliomas. This chart shows the overall profitability of the oncology sector. It reflects the willingness of investors to fund breakthrough but risky developments and the overall progress of the sector in the fight against cancer.
Overall market profit
Chimerix is a biopharmaceutical company developing antiviral and cancer drugs. Its value is determined by the potential of its scientific developments. The overall market situation, shown in this chart, does not influence the progress of research, but is a key factor in attracting the capital from investors needed to conduct expensive clinical trials.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Chimerix Inc.
Chimerix is a biopharmaceutical company developing drugs to treat serious diseases, including cancer. Its financial future depends on the success of clinical trials. This chart reflects analysts' expectations for the commercial potential of its developments, in particular, the smallpox prevention drug sold to Emergent BioSolutions.
%20profit%20of%20the%20company%20Chimerix%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Chimerix-Inc.&v=1772513513981 "Graph of future (projected) profit of the company Chimerix Inc.")
Future (predicted) profit of companies in the market segment - General oncology therapy
Chimerix is a biotech company developing drugs to treat serious diseases, including cancer and viral infections. Its success depends on the results of clinical trials and the commercialization of its developments. The chart below reflects profitability projections for the entire biotech sector, providing context for assessing Chimerix's potential and risks.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772513513997 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
Chimerix is a biopharmaceutical company developing drugs to treat cancer and other serious diseases. Its success at this stage depends on the results of clinical trials and strategic partnerships. The overall economic forecasts shown in this chart are of minimal importance to the company.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513514017 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Chimerix Inc.
Chimerix is a biopharmaceutical company with an FDA-approved drug. This chart shows how the market perceives the commercial success of this product and the potential of the rest of its pipeline. This trend reflects how effectively the company is building sales and marketing for its key asset.
P/S market segment - General oncology therapy
Chimerix is a biopharmaceutical company developing drugs to treat serious diseases, including oncology. Revenue depends on the success of its development and sales of approved products. This pharmaceutical sector chart helps assess how the market views Chimerix's scientific platform and the commercial potential of its drug candidates.
P/S of the market as a whole
Chimerix is a biotech company developing treatments for serious diseases. Its main commercial product is an antiviral drug approved for the treatment of smallpox. This market revenue valuation chart helps understand how investors value a company with a single commercial product and an early-stage pipeline.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Chimerix Inc.
Chimerix is a biopharmaceutical company developing drugs to treat serious diseases, including oncology and viral infections. This chart shows how the market assesses the future commercial potential of its developments. It reflects investor expectations for clinical trial success and strategic partnerships that could generate revenue.
%20P%2FS%20Chimerix%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Chimerix-Inc.&v=1772513514142 "The graph of the company's future (projected) P/S Chimerix Inc.")
Future (projected) P/S of the market segment - General oncology therapy
Chimerix is a biopharmaceutical company whose primary asset, Tembexa, is an FDA-approved smallpox treatment sold to Emergent BioSolutions, with royalties retained. The company's valuation reflects both the potential revenue from Tembexa (particularly in the context of biosafety) and the prospects of its oncology development pipeline.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772513514151 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
Chimerix, Inc. is a biopharmaceutical company developing drugs to treat serious diseases, including oncology. Its prospects depend on scientific breakthroughs. In the context of the overall revenue forecasts shown in the chart, Chimerix represents a bet on medical innovation.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513514200 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Chimerix Inc.
Chimerix is a biopharmaceutical company whose main commercial product is TEMBEXA, a treatment for smallpox. Revenue, shown in this chart, is generated primarily through government contracts to supply this drug to the Strategic National Biosecurity Stockpile.
Sales of companies in the market segment - General oncology therapy
Chimerix (CMRX) is a biopharmaceutical company developing drugs to treat cancer and other serious diseases. Its lead candidate, ONC201, has demonstrated activity in the treatment of glioma. This figure reflects revenue in the oncology sector. Chimerix is working to develop targeted therapies for difficult-to-treat cancers, which could bring new hope to patients.
Overall market sales
Chimerix is a biopharmaceutical company developing drugs to treat serious diseases, including cancer. Its success depends on scientific breakthroughs and funding. This pattern of overall economic activity influences the investment climate in the biotech industry. Growing markets facilitate raising capital for costly clinical trials.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Chimerix Inc.
Chimerix is a biopharmaceutical company developing treatments for serious diseases, including cancer and viral infections. Its revenue depends on sales of its approved drug, TEMBEXA, and the success of its other developments. This chart reflects analyst revenue forecasts, which are an estimate of the commercial potential of its product portfolio and research.
%20sales%20of%20the%20company%20Chimerix%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Chimerix-Inc.&v=1772513514361 "Schedule of future (projected) sales of the company Chimerix Inc.")
Future (projected) sales of companies in the market segment - General oncology therapy
Chimerix is a biopharmaceutical company developing drugs to treat serious diseases. This forecast chart reflects potential future revenue from their commercial product and development pipeline. It represents analysts' views on the market potential of their antiviral and oncology programs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772513514401 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
Chimerix is a biotechnology company developing drugs to treat oncology. Its future depends on the success of clinical trials and strategic decisions. This chart illustrates the overall investment climate, which influences funding, but the key factor for Chimerix is scientific progress and the potential of its developments to change the standard of cancer treatment.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513514432 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Chimerix Inc.
Chimerix is a biopharmaceutical company developing antiviral and cancer drugs. Its profitability can be highly variable, often depending on government contracts (as in the case of its smallpox drug) or the success of new developments. The chart shows how the company translates its scientific achievements into financial results.
Market segment marginality - General oncology therapy
Chimerix is a biopharmaceutical company developing drugs to treat serious diseases. Its first approved product, Tembexa, is designed to treat smallpox. This chart shows the company's profitability. Success depends on government contracts for Tembexa and progress in developing other drugs, such as those in oncology.
Market marginality as a whole
Chimerix, Inc. is a biopharmaceutical company developing drugs to treat serious diseases, including cancer. Its value depends on the success of clinical trials. This total return chart reflects the market's willingness to finance risky biotech projects. During periods of economic growth, investors are more inclined to make such investments.
Employees in the company, segment and market as a whole
Number of employees in the company Chimerix Inc.
Chimerix is a biopharmaceutical company developing drugs to treat serious diseases, particularly oncology. Its strategy includes both internal development and acquisitions. This chart shows how the size of the research team changes depending on clinical trial progress and strategic decisions regarding portfolio development.
Share of the company's employees Chimerix Inc. within the market segment - General oncology therapy
Chimerix is a biopharmaceutical company developing drugs to treat serious diseases, including cancer. Its clinical development team consists of highly qualified scientists and physicians. This chart shows the company's investment in research and development to transform promising molecules into life-saving treatments.
Number of employees in the market segment - General oncology therapy
Chimerix, Inc. is a biopharmaceutical company developing drugs to treat cancer and other serious diseases. This chart, showing employment in oncology therapeutics, illustrates the scale and complexity of this field. For Chimerix, the growing number of researchers means both accelerated scientific discovery and intense competition for funding and breakthrough results.
Number of employees in the market as a whole
Chimerix is a biotech company developing drugs to treat serious diseases, including cancer. Bringing a new drug to market requires significant investment. A healthy economy, reflected by the growth in overall employment in this chart, facilitates the influx of capital into the biotech sector, allowing companies like Chimerix to fund their research and development.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Chimerix Inc. (CMRX)
Chimerix (CMRX) is a biopharmaceutical company developing treatments, including in oncology. In this sector, market capitalization is rarely correlated with current revenue or headcount. This chart reflects the market's valuation of their scientific platform and R&D capabilities. Investors are betting on the intellectual capital contained within a small research team.
%20of%20the%20company%20Chimerix%20Inc.%20(CMRX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Chimerix-Inc.-CMRX&v=1772513514650 "Chart of market capitalization per employee (in thousands of dollars) of the company Chimerix Inc. (CMRX)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
Chimerix is a biotech company developing drugs to treat serious diseases. Its value is determined by the potential of its scientific platform. This metric reflects the market premium placed on the company's innovations per scientist capable of creating a life-saving treatment.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772513514667 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Chimerix is a biotech company that developed a smallpox treatment, which is now included in the US Strategic National Stockpile. This provides the company with a stable income. This chart for Chimerix shows how holding a government contract for an important medical product can generate high and stable returns per employee.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513514689 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Chimerix Inc. (CMRX)
Chimerix is a biotech company with one approved drug (Tembexa), but its focus is on R&D. This chart shows the balance. It reflects the extent to which revenue from one product can cover the high R&D costs incurred by each researcher working on future drugs.
%20Chart%20Chimerix%20Inc.%20(CMRX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Chimerix-Inc.-CMRX&v=1772513514771 "Company Profit Per Employee (in thousands of dollars) Chart Chimerix Inc. (CMRX)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
Chimerix is a biopharmaceutical company developing antiviral and oncology drugs. For companies like this, the productivity of their research and development team is critical. This chart allows us to assess how effectively each employee, from the scientist to the clinical trial manager, contributes to the creation of intellectual property and future profits.
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772513514828 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Chimerix is a biotech company that historically focused on antiviral drugs and is now focused on oncology. This chart shows the average profitability of one employee in the economy. It provides investors with context: the biotech sector operates in an all-or-nothing paradigm, where the return on personnel (scientists) can be colossal if successful.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513514969 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Chimerix Inc. (CMRX)
Chimerix is a biopharmaceutical company that developed a smallpox treatment, which was sold to Emergent BioSolutions. Its revenue per employee now depends on royalties and the development of its remaining oncology assets. The chart illustrates this transition phase, where revenue from past successes funds future research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Chimerix-Inc.-CMRX&v=1772513515016 "Sales chart per company employee Chimerix Inc. (CMRX)")
Sales per employee in the market segment - General oncology therapy
Chimerix (CMRX) is a biopharmaceutical company best known for its antiviral drug Tembexa (used to treat smallpox). This chart shows the average revenue per employee in the segment. It allows investors to assess how effectively Chimerix utilizes its team to generate revenue from its approved drugs and R&D compared to its competitors.
Sales per employee for the market as a whole
Chimerix (CMRX) is a biotech company that developed Tembexa (a smallpox treatment), which was sold to Emergent BioSolutions. The company is now focused on oncology. This metric reflects the revenue (royalties or milestone payments) the company generates by using its small staff of scientists to develop new oncology drugs.
Short shares by company, segment and market as a whole
Shares shorted by company Chimerix Inc. (CMRX)
Chimerix (CMRX) is a biotech that recently sold its lead approved drug, Tembexa, and is now betting on the remaining oncology pipeline. This chart shows short interest. The rise in short bets reflects market skepticism about the new strategy, concerns about high burn rates, and the risk that new drugs won't prove effective. (349)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Chimerix-Inc.-CMRX&v=1772513515158 "Short Shares Chart for the Company Chimerix Inc. (CMRX)")
Shares shorted by market segment - General oncology therapy
Chimerix (CMRX) is a biopharmaceutical company developing drugs to treat serious diseases, including cancer. The chart below shows the total short position in the biotech sector. It's a sentiment barometer, showing how many investors overall don't believe in the success of risky clinical trials.
Shares shorted by the overall market
Chimerix is a biotech focused on oncology and biodefense (smallpox drug). This chart illustrates the overall market pessimism. Investors see a company dependent on R&D and irregular government contracts. In times of fear, the market is unwilling to tolerate such uncertainty and sells off shares.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Chimerix Inc. (CMRX)
Chimerix (CMRX) is a biotech company that sold its main asset and is now focusing on oncology. Its large cash position makes it unusual. This oscillator measures momentum. It shows when the stock is overheated (above 70) due to news of new developments or oversold (below 30) due to a lack of news flow.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Chimerix-Inc.-CMRX&v=1772513515254 "RSI 14 indicator chart for the company's stock Chimerix Inc. (CMRX)")
RSI 14 Market Segment - General oncology therapy
Chimerix is a biotech company developing cancer treatments. Their lead candidate, ONC201, targets rare brain tumors (gliomas). This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire speculative segment is overheated.
RSI 14 for the overall market
For Chimerix, a biotech company in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is turned off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CMRX (Chimerix Inc.)
Chimerix is a biopharmaceutical company focused on oncology. After selling its approved drug Tembexa, the company focused its resources on expanding its R&D portfolio. This chart shows the average price target from analysts, which is almost entirely dependent on their confidence in the success of clinical trials of the company's new oncology drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CMRX-Chimerix-Inc.&v=1772513515339 "A chart showing analyst consensus forecasts for the expected stock price. CMRX (Chimerix Inc.)")
The difference between the consensus estimate and the actual stock price CMRX (Chimerix Inc.)
Chimerix is a biopharmaceutical company focused on developing oncology drugs, specifically ONC201 for the treatment of brain tumors. This chart shows how far the current share price differs from the "fair" value predicted by analysts. For an R&D company, this gap reflects the experts' confidence in the success of their clinical trials and the potential to become a new standard of care.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CMRX-Chimerix-Inc.&v=1772513515366 "A chart showing the difference between the consensus forecast and the actual stock price. CMRX (Chimerix Inc.)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
Chimerix is a biotech company making risky bets on oncology R&D. Its success depends on breakthroughs in cancer treatment. This chart shows analysts' overall expectations not for Chimerix itself, but for the entire oncology sector. It reflects whether experts believe in new R&D platforms or believe the entire industry is headed for decline.
Analysts' consensus forecast for the overall market share price
Chimerix is a biotech company specializing in developing cancer treatments. This is a high-risk sector, where success depends on the results of clinical trials. This chart reflects the overall risk appetite in the market. When analysts are bullish (the chart rises), investors are more willing to fund long-term, risky projects, such as Chimerix's drug development.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Chimerix Inc.
Chimerix is a biotech company that has undergone a transformation. Having sold their approved antiviral drug (Tembexa), they are now fully focused on oncology, developing immunotherapy (IoT). For such an R&D company, this chart is a binary risk barometer. It aggregates not sales, but rather the market's assessment of their scientific pipeline and their ability to bring their developments to FDA approval.
AKIMA Market Segment Index - General oncology therapy
Chimerix is a biopharmaceutical company focused on developing cancer treatments. In the field of general oncology, where competition is fierce and R&D costs are enormous, it's important for investors to understand whether a company stands out. This chart shows the average composite index for the entire segment, allowing investors to quickly assess whether CMRX is ahead or behind its competitors.
The AKIM Index for the overall market
Chimerix is a biopharmaceutical company developing cancer treatments (ONC201 for glioma). This chart, which reflects the market average, provides a macro backdrop. It helps assess how the company, having sold its antiviral business, compares to overall economic trends in oncology.
